Cathi Ahearn is a seasoned biopharma executive with more than 25 years of commercialization, development, and portfolio management experience across multiple therapeutic areas in the US and globally. She is a strategic and results-oriented leader who is passionate about the power of cross-functional collaboration to advance outcomes for patients.
In her role leading Enterprise Strategy, Ahearn is a member of the Executive Leadership Team at Bristol Myers Squibb and is accountable for Corporate and Portfolio Strategy, Portfolio Analytics and Enterprise Governance. Ahearn joined BMS in 2021 to lead global marketing and commercial development, and to build strategic portfolio management capabilities for the organization. Prior to joining BMS, Ahearn spent more than two decades in roles of increasing responsibility and scope at Roche/Genentech, primarily in oncology. During her tenure there, Ahearn was the global program leader for Roche’s anti-PDL1 program from the time of its entry into clinic through its broad therapeutic expansion, global licensing, and commercialization and over the course of her career, has held a broad range of sales, marketing, and strategic roles.
Ahearn holds a Bachelor of Arts in Psychology from UCLA and a Master of Business Administration from the Fuqua School of Business at Duke University.